To assess the effects of mTOR inhibitors and CCL20 on HNSCC cell growth, we treated the SAS and FaDu cells with different concentrations of rapamycin (1–100 μM), BEZ235 (1–10 μM), or CCL20 (1–1000 ng/mL) using a WST-1 assay. This evidence concerns the gene CCL20 and head and neck squamous cell carcinoma.